Trump to discuss new autism findings after indicating a serious discovery during Kirk Memorial

At the Memorial of Charlie Kirk, president Donald Trump The off-conscript script to reveal that its administration has discovered new autism arrangements. He suggested that the upcoming briefing of public health would examine the possible connections between acetaminphone, widely sold as Tynol and a disorder of the autism spectrum (ASD).

Reports suggest that Trump’s comments can also extend to the warning of pregnant women with routine use of acetaminofen, signaling a controversial shift of health tips that could cause a nationwide debate.

Trump’s planned comments are expected to emphasize leukovorine, a drug traditionally used in anemia and some cancer treatment as a potential therapy to improve communication skills in children with autism.

The briefing was attended by health secretary Robert F. Kennedy Jr., Commissioner FDA Marta Makara and administrator CMS Mehmet OZ.

Background: Tymnol tests and autism

The announcement arises in connection with the growing fears of the public about environmental and pharmaceutical factors contributing to autism. Tynol or acetaminofen is widely used during pregnancy to reduce fever and pain treatment.

Some studies have he suggested a possible association Between prenatal exposure to acetaminofen and developmental disorders, although the findings remain ambiguous.

Autism diagnosis in the United States has increased over the past two decades. Data from Disease control and prevention centers Indicate that 1 out of 31 American 8-year-olds were diagnosed with autism, compared to 1 in 150 in 2000.

The administration cited environmental toxins as a possible co -creator, while many experts emphasize that improving diagnosis and greater awareness are probably the key factors of growing numbers.

Leukovorine emphasized as potential autism treatment

In addition to warning about so much, White House It is expected to focus on leukoworine as potential treatment. Early research suggests that the drug can improve communication and cognitive functions in some children with autism.

Leukoworin is a derivative of folic acid and was traditionally used to treat some forms of anemia and counteracting side effects of chemotherapy.

Experts emphasize that leukovorine studies remain preliminary. Clinical trials are underway, and scientists emphasize that the results should be interpreted carefully before the drug is widely recommended as standard autism treatment.

The medical community raises concerns

The proposed guidelines caused concern among healthcare professionals. Many doctors say that current evidence does not confirm the final relationship between the use of acetaminofen during pregnancy and autism.

American College of Obstetricians and Gynecologists and American Academy of Pediatrics still consider security acetaminofen when it is treated as recommended.

Kenvue, a manufacturer of T by Tyroin, published a statement in which it was stated that there was no decisive evidence connecting acetaminofen with autism.

Experts warn that public confusion regarding these claims may lead to unnecessary avoidance of drugs and potential health threats, especially when fever treatment is crucial during pregnancy.

Implications for public health

Trump’s announcement is a significant change in messages around the use of acetaminofen during pregnancy. Although the tips are not legally binding, it can affect public behavior, prenatal care practices and media relationships.

Healthcare providers are encouraged to discuss the risk and benefits of patients and to inform about current research.

Further research is expected to both exposure to acetaminophen and potential treatment of autism, including leukovorine, will provide more clear tips in the coming years. Regulatory agencies, including the FDA, strictly monitor the situation to assess all the corrections of the rules.